Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Assets Average (2016 - 2026)

Gyre Therapeutics has reported Assets Average over the past 15 years, most recently at $162.8 million for Q4 2025.

  • Quarterly Assets Average rose 29.87% to $162.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $162.8 million through Dec 2025, up 29.87% year-over-year, with the annual reading at $145.8 million for FY2025, 20.5% up from the prior year.
  • Assets Average was $162.8 million for Q4 2025 at Gyre Therapeutics, up from $156.0 million in the prior quarter.
  • Over five years, Assets Average peaked at $162.8 million in Q4 2025 and troughed at $11.2 million in Q3 2023.
  • The 5-year median for Assets Average is $98.6 million (2021), against an average of $90.9 million.
  • Year-over-year, Assets Average tumbled 80.45% in 2023 and then soared 1001.03% in 2024.
  • A 5-year view of Assets Average shows it stood at $67.1 million in 2021, then decreased by 13.73% to $57.9 million in 2022, then grew by 9.27% to $63.3 million in 2023, then soared by 98.13% to $125.3 million in 2024, then rose by 29.87% to $162.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Assets Average are $162.8 million (Q4 2025), $156.0 million (Q3 2025), and $141.2 million (Q2 2025).